2021
Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St. Hillien SA, Kalim S, Nigwekar SU, Flood JG, Nixon A, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Regner KR, Belcher JM, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT. Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. Clinical And Translational Gastroenterology 2021, 12: e00359. PMID: 33979307, PMCID: PMC8116001, DOI: 10.14309/ctg.0000000000000359.Peer-Reviewed Original ResearchConceptsNeutrophil gelatinase-associated lipocalinUrinary neutrophil gelatinase-associated lipocalinAcute kidney injuryAcute tubular necrosisPrerenal acute kidney injuryHepatorenal syndromeKidney injuryC-statisticManagement of AKITypes of AKIEnd-stage liver disease (MELD) scoreTransplant-free survivalLiver Disease scoreMedian serum creatinineGelatinase-associated lipocalinPrediction of mortalityNet reclassification indexDiscrimination incrementProspective cohortSerum creatinineTubular necrosisProspective studyReclassification indexUnadjusted analysesPrognostic marker
2014
Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis
Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, Lim J, Coca SG, Parikh CR. Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. Clinical Journal Of The American Society Of Nephrology 2014, 9: 1857-1867. PMID: 25183658, PMCID: PMC4220770, DOI: 10.2215/cjn.09430913.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-Phase ProteinsAdultAgedAlbuminuriaBiomarkersDisease ProgressionFatty Acid-Binding ProteinsFemaleHepatitis A Virus Cellular Receptor 1Hospital MortalityHumansInterleukin-18Lipocalin-2LipocalinsLiver CirrhosisMaleMembrane GlycoproteinsMiddle AgedPredictive Value of TestsProspective StudiesProto-Oncogene ProteinsReceptors, VirusSodiumConceptsProgression of AKIAKI progressionIL-18Urinary biomarkersHospital mortalityKIM-1End-stage liver disease (MELD) scoreL-FABPStage liver disease scoreNeutrophil gelatinase-associated lipocalinAKI Network criteriaLiver Disease scoreProspective cohort studyGelatinase-associated lipocalinNet reclassification indexUnited States medical centersKey clinical variablesRobust clinical modelKidney injuryCohort studySevere complicationsLiver cirrhosisRisk stratificationClinical variablesMarker levels